Theres a clinical emphasis on collaborative, patient-tailored approaches: GLP-1 use should be based on shared decision-making of the patient with the care team Healthcare staff need to be aware of factors like: Elevated symptom prevalence during the titration phase Dose magnitude and how side effect prevalence increases accordingly Daily oral vs
Mild to moderate nausea in the first 12 weeks is a normal part of treatment adaptation and does not predict long-term tolerability
This method can serve as an effective alternative for supplementation, especially for those who prefer a more gentle and less invasive approach
GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs (Wegovy) for SC administration for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), for use in combination with a reduced calorie diet and increased physical activity
Since the GLP-1 agonist drugs, which are approved by the FDA, are known to regulate this natural hormone and provide the same effects, the GLP-1 patches are named after these drugs